Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ketoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 6/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CXCR1 | P25024 | 2/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ketoprofen SCHEMBL2896 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| R-Ketoprofen SCHEMBL195303 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL8577572 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Dexketoprofen SCHEMBL29396875 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL16757741 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL679920 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Dexketoprofen SCHEMBL66987 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| R-Ketoprofen SCHEMBL29353694 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL3843886 | 1.00 | PTGS1 (1.00) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 | |
| Ketoprofen SCHEMBL23391019 | 0.98 | PTGS1 (0.97) | PTGS1PTGS2MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120128588-A1 | ISOTOPE LABELED 2-ARYLPROPIONIC ACID COMPOUNDS AND PROCESS FOR PRODUCTION OF SAME, AND MOLECULAR PROBE FOR POSITRON EMISSION TOMOGRAPHY AND METHOD FOR IMAGING OF CYCLOOXYGENASE AND THE LIKE USING SAME | RIKEN (JP) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128588-A1 | ISOTOPE LABELED 2-ARYLPROPIONIC ACID COMPOUNDS AND PROCESS FOR PRODUCTION OF SAME, AND MOLECULAR PROBE FOR POSITRON EMISSION TOMOGRAPHY AND METHOD FOR IMAGING OF CYCLOOXYGENASE AND THE LIKE USING SAME | CYP2F1, PTGS2, PTGER2 | PTGS1 5/4885PTGS2 2/4885MAPT 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.